Cellular immunity to the Her-2/neu protooncogene.

[1]  C. Peschel,et al.  Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. , 2002, Cancer research.

[2]  J. Baselga,et al.  Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. , 2001, Journal of the National Cancer Institute.

[3]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[4]  Piero Musiani,et al.  Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.

[5]  G. Pawelec,et al.  Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope , 2001, British Journal of Cancer.

[6]  F. Lemonnier,et al.  Identification of HER‐2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors , 2001, European journal of immunology.

[7]  J. Baselga.  Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials , 2001, Oncology.

[8]  C. Thoburn,et al.  The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen. , 2001, Clinical immunology.

[9]  A. Scott,et al.  Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Piechocki,et al.  Vaccination with Cytoplasmic ErbB-2 DNA Protects Mice from Mammary Tumor Growth Without Anti-ErbB-2 Antibody1 , 2001, The Journal of Immunology.

[11]  M. Piechocki,et al.  Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat. , 2001, Cellular immunology.

[12]  M. Piechocki,et al.  Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-21 , 2001, The Journal of Immunology.

[13]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[14]  R. Kiessling,et al.  Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. , 2001, Blood.

[15]  C. Peschel,et al.  The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells1 , 2001, The Journal of Immunology.

[16]  Alessandro Sette,et al.  Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A∗0201-Binding Affinity1 , 2001, The Journal of Immunology.

[17]  R. Zinkernagel,et al.  IgA production without μ or δ chain expression in developing B cells , 2001, Nature Immunology.

[18]  P. Dennis,et al.  Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. , 2001, Cancer research.

[19]  R. Tisch,et al.  Class I Major Histocompatibility Complex Anchor Substitutions Alter the Conformation of T Cell Receptor Contacts* , 2001, The Journal of Biological Chemistry.

[20]  M. Gnant,et al.  Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  T. Foy,et al.  Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. , 2001, Vaccine.

[22]  S. Braun,et al.  ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. , 2001, Cancer research.

[23]  F. Fallarino,et al.  Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  P. Musiani,et al.  Insertion of the DNA for the 163–171 peptide of IL1β enables a DNA vaccine encoding p185neu to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice , 2001, Gene Therapy.

[25]  A. Ullrich,et al.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. , 2001, Endocrine-related cancer.

[26]  K. Knutson,et al.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.

[27]  E. Jaffee,et al.  The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. , 2001, Cancer research.

[28]  B. Seliger,et al.  Characterization of the Major Histocompatibility Complex Class I Deficiencies in B 16 Melanoma Cells 1 , 2001 .

[29]  J. Weber,et al.  Phase I Trial Of Intravenous Peptide-Pulsed Dendritic Cells in Patients With Metastatic Melanoma , 2001, Journal of immunotherapy.

[30]  Mark M. Davis,et al.  Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma , 2000, The Journal of experimental medicine.

[31]  K. Chien,et al.  Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. , 2000, Seminars in oncology.

[32]  D. Jäger,et al.  Vaccination for Malignant Melanoma: Recent Developments , 2000, Oncology.

[33]  Piero Musiani,et al.  DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.

[34]  L. Kanz,et al.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000, Blood.

[35]  E. Appella,et al.  Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. , 2000, Cancer research.

[36]  B. Seliger,et al.  Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.

[37]  W. Urba,et al.  Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice , 2000, International journal of cancer.

[38]  B. Seliger,et al.  HER‐2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA‐A2.1‐restricted cytotoxic T lymphocytes , 2000, International journal of cancer.

[39]  S. Rosenberg,et al.  Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules , 2000, The Journal of Immunology.

[40]  R. Coppari,et al.  DNA vaccination with full-length or truncated Neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice , 2000, Gene Therapy.

[41]  A. Ullrich,et al.  Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor - convergence point for signal integration and diversification , 2000, Breast Cancer Research.

[42]  M. Hung,et al.  HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* , 2000, The Journal of Biological Chemistry.

[43]  R. Zinkernagel,et al.  Immunotherapy with Dendritic Cells Directed against Tumor Antigens Shared with Normal Host Cells Results in Severe Autoimmune Disease , 2000, The Journal of experimental medicine.

[44]  T. Deerinck,et al.  Aberrant development of motor axons and neuromuscular synapses in erbB2-deficient mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Shuqin Yan,et al.  Poor Binding of a HER-2/neu Epitope (GP2) to HLA-A2.1 Is due to a Lack of Interactions with the Center of the Peptide* , 1999, The Journal of Biological Chemistry.

[46]  G. Cornelis,et al.  Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. , 1999, Journal of immunology.

[47]  E. Gilboa.  The makings of a tumor rejection antigen. , 1999, Immunity.

[48]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Shabanowitz,et al.  Mass‐spectrometric evaluation of HLA‐A*0201‐associated peptides identifies dominant naturally processed forms of CTL epitopes from MART‐1 and gp100 , 1999 .

[50]  S. Shak.  Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. , 1999, Seminars in oncology.

[51]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[52]  P. Paz,et al.  Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC I-dependent peptide trimming in the ER. , 1999, Immunity.

[53]  A Sette,et al.  Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. , 1999, Journal of immunology.

[54]  M. Cheever,et al.  Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  Y. Yarden,et al.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[56]  A. Sette,et al.  Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. , 1999, Cancer research.

[57]  B. Stockinger,et al.  DNA Vaccination:  Transfection and Activation of Dendritic Cells as Key Events for Immunity , 1999, The Journal of experimental medicine.

[58]  A. Amici,et al.  Genetic immunization against neu /erbB2 transgenic breast cancer , 1998, Cancer Immunology, Immunotherapy.

[59]  S. Rosenberg,et al.  Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. , 1998, Cancer research.

[60]  A. Sette,et al.  Identification of HER2/neu‐derived peptide epitopes recognized by gastric cancer‐specific cytotoxic T lymphocytes , 1998, International journal of cancer.

[61]  K. Chow,et al.  Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. , 1998, The Annals of thoracic surgery.

[62]  T. Griffith,et al.  TRAIL: a molecule with multiple receptors and control mechanisms. , 1998, Current opinion in immunology.

[63]  P. Kloetzel,et al.  The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope , 1998, The Journal of experimental medicine.

[64]  P. Musiani,et al.  Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER‐2/neu transgenic mice , 1998, International journal of cancer.

[65]  J. Ross,et al.  Prognostic factors in gastric cancer. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[66]  J. Murray,et al.  Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[67]  G. Gaudernack,et al.  Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer , 1998, Vox sanguinis.

[68]  T. Kipps,et al.  DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. , 1998, Cancer research.

[69]  D. Opel,et al.  Neuregulins Promote Survival and Growth of Cardiac Myocytes , 1998, The Journal of Biological Chemistry.

[70]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[71]  C. Melief,et al.  Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.

[72]  Y. Yarden,et al.  The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. , 1998, Biochimica et biophysica acta.

[73]  H. Rammensee,et al.  Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.

[74]  G. Steger,et al.  Soluble HER‐2/neu neutralizes biologic effects of anti‐HER‐2/neu antibody on breast cancer cells in vitro , 1997, International journal of cancer.

[75]  W. Wells,et al.  The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[76]  S. Sanz,et al.  The prognostic value of HER-2/neu oncogene in cervical cancer. , 1997, Annals of clinical and laboratory science.

[77]  R. Steinman,et al.  Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors , 1997, The Journal of experimental medicine.

[78]  M. Mai,et al.  Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. , 1997, The American journal of pathology.

[79]  A. Bai,et al.  The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules. , 1997, Journal of immunology.

[80]  M. Bevan,et al.  Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. , 1997, Blood.

[81]  M. Pfreundschuh,et al.  Serological analysis of human tumor antigens: molecular definition and implications. , 1997, Molecular medicine today.

[82]  H. Ikeda,et al.  Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. , 1997, Journal of immunology.

[83]  Persons Dl,et al.  Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization , 1997 .

[84]  B. Seliger,et al.  TAP off--tumors on. , 1997, Immunology today.

[85]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[86]  K. Pavelić,et al.  The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. , 1997, Gastroenterology.

[87]  D. Laface,et al.  Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. , 1997, Human immunology.

[88]  M. Provinciali,et al.  Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA , 1997, Cancer Immunology, Immunotherapy.

[89]  E. Halapi,et al.  Mechanisms of escape from CD8+ T‐cell clones specific for the HER‐2/NEU proto‐oncogene expressed in ovarian carcinomas: Related and unrelated to decreased MHC class 1 expression , 1997, International journal of cancer.

[90]  F. Garrido,et al.  High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. , 1996, Tissue antigens.

[91]  Hans-Georg Rammensee,et al.  Coordinated Dual Cleavages Induced by the Proteasome Regulator PA28 Lead to Dominant MHC Ligands , 1996, Cell.

[92]  J. Gralow,et al.  Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines , 1996 .

[93]  Hans-Georg Rammensee,et al.  A role for the proteasome regulator PA28α in antigen presentation , 1996, Nature.

[94]  J. Gralow,et al.  Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. , 1996, Journal of immunology.

[95]  C. Hauser,et al.  Oncogenic Neu/ErbB-2 Increases Ets, AP-1, and NF-B-dependent Gene Expression, and Inhibiting Ets Activation Blocks Neu-mediated Cellular Transformation (*) , 1996, The Journal of Biological Chemistry.

[96]  C. Hahn,et al.  The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen , 1996, The Journal of experimental medicine.

[97]  Kuo‐Ting Chang,et al.  Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. , 1996, Cancer research.

[98]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[99]  J. Schlom,et al.  Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses , 1996, European journal of immunology.

[100]  R. Chirino,et al.  Validation of a differential PCR and an ELISA procedure in studying HER‐2/neu status in breast cancer , 1996, International journal of cancer.

[101]  A. Harris,et al.  Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. , 1995, Cancer research.

[102]  F. Waldman,et al.  ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. , 1995, Cancer research.

[103]  T. Eberlein,et al.  Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. , 1995, Journal of immunology.

[104]  A. El‐Naggar,et al.  HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. , 1995, Archives of otolaryngology--head & neck surgery.

[105]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[106]  T. Eberlein,et al.  Shared T cell epitopes in epithelial tumors. , 1995, Cellular immunology.

[107]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[108]  T. Eberlein,et al.  Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[109]  O. Cussenot,et al.  Oncogene amplifications in early‐stage human prostate carcinomas , 1994, International journal of cancer.

[110]  L. Seymour,et al.  Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. , 1994, British journal of cancer.

[111]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[112]  A. Gazdar,et al.  HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. , 1994, Cancer research.

[113]  V. Gnau,et al.  Analysis of a naturally occurring HLA class I-restricted viral epitope. , 1994, Immunology.

[114]  T. Eberlein,et al.  TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. , 1994, Journal of immunology.

[115]  T. Eberlein,et al.  Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. , 1994, Journal of immunology.

[116]  O. Kallioniemi,et al.  Elevated erbB‐2 oncoprotein levels in preoperative and follow‐up serum samples define an aggressive disease course in patients with breast cancer , 1994, Cancer.

[117]  S. Ménard,et al.  Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. , 1993, Cancer research.

[118]  T. Eberlein,et al.  HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. , 1993, Journal of immunology.

[119]  J. Wharton,et al.  Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. , 1993, Cellular immunology.

[120]  H. Friess,et al.  Overexpression of HER2/neu oncogene in human pancreatic carcinoma. , 1993, Human pathology.

[121]  H. Schreiber,et al.  CD4+ AND B LYMPHOCYTES IN TRANSPLANTATION IMMUNITY: II. AUGMENTED REJECTION OF TUMOR ALLOGRAFTS BY MICE LACKING B CELLS , 1993, Transplantation.

[122]  D. Beer,et al.  Amplification and over‐expression of the EGFR and erbB‐2 genes in human esophageal adenocarcinomas , 1993, International journal of cancer.

[123]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[124]  P. Cresswell,et al.  Cytokines increase transporter in antigen processing-1 expression more rapidly than HLA class I expression in endothelial cells. , 1992, Journal of immunology.

[125]  H. Höfler,et al.  Expression of HER‐2/neu in renal‐cell carcinoma. Correlation with histologic subtypes and differentiation , 1992, International journal of cancer.

[126]  G. Kaplan,et al.  Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing , 1992, The Journal of experimental medicine.

[127]  J. Wharton,et al.  Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. , 1991, Cancer research.

[128]  R. Freedman,et al.  Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. , 1991, Journal of immunology.

[129]  J. Berek,et al.  Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. , 1990, Cancer research.

[130]  T. Strohmeyer,et al.  Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. , 1990, Cancer research.

[131]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[132]  T. Yagi,et al.  Induction of a variety of tumors by c‐erbB2 and clonal nature of lymphomas even with the mutated gene (Val659‐‐‐‐Glu659). , 1990, The EMBO journal.

[133]  Antonio Lanzavecchia,et al.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.

[134]  M. Vijver,et al.  The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues , 1989, Histopathology.

[135]  P. Quirke,et al.  Pattern of expression of c-erbB-2 oncoprotein in human fetuses. , 1989, British Journal of Cancer.

[136]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[137]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[138]  H. Shepard,et al.  Resistance of tumor cells to tumor necrosis factor , 1988, Journal of Clinical Immunology.

[139]  A. Ullrich,et al.  Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[140]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[141]  E. Klein,et al.  Auto-tumor immunity in patients with solid tumors: participation of CD3 complex and MHC class I antigens in the lytic interaction. , 1987, Immunology letters.

[142]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[143]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[144]  M. Bennett,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTORS IN HUMAN BLADDER CANCER: COMPARISON OF INVASIVE AND SUPERFICIAL TUMOURS , 1985, The Lancet.

[145]  R. Zinkernagel,et al.  Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system , 1974, Nature.

[146]  G. Habicht,et al.  Kinetic Differences in Unresponsiveness of Thymus and Bone Marrow Cells , 1971, Science.

[147]  T. Ivert,et al.  Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture — No correlation with the postsurgical clinical course , 2004, Cancer Immunology, Immunotherapy.

[148]  J. Murray,et al.  Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity , 2004, Molecular and Cellular Biochemistry.

[149]  M. Campiglio,et al.  HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[150]  Y. Yarden,et al.  The basic biology of HER2. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[151]  D. McNeel,et al.  Clinical translation of peptide-based vaccine trials: the HER-2/neu model. , 2001, Critical reviews in immunology.

[152]  Y. Yarden,et al.  Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.

[153]  K. Akiyoshi,et al.  Development of a cancer vaccine: peptides, proteins, and DNA , 2000, Cancer Chemotherapy and Pharmacology.

[154]  H. Ragde,et al.  Infusion of dendritic cells pulsed with HLA‐A2‐specific prostate‐specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone‐refractory metastatic disease , 1999, The Prostate.

[155]  Alessandro Sette,et al.  The optimization of helper T lymphocyte (HTL) function in vaccine development , 1998, Immunologic research.

[156]  P. Cresswell,et al.  Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.

[157]  A. Sette,et al.  The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. , 1998, Human immunology.

[158]  M. Cheever,et al.  HER-2/neu oncogenic protein: issues in vaccine development. , 1998, Critical reviews in immunology.

[159]  T. Blankenstein,et al.  B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.

[160]  H. Klocker,et al.  Dendritic cells for the immunotherapy of renal cell carcinoma. , 1997, Urologia internationalis.

[161]  M. Lotze,et al.  Dendritic Cell Based Therapy of Cancer , 1997 .

[162]  A. Gazdar,et al.  Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. , 1996, Cancer research.

[163]  T. Hunter,et al.  Receptor protein-tyrosine kinases and their signal transduction pathways. , 1994, Annual review of cell biology.

[164]  P. Srivastava,et al.  Heat shock protein-peptide complexes in cancer immunotherapy. , 1994, Current opinion in immunology.

[165]  V. Engelhard,et al.  Structure of peptides associated with class I and class II MHC molecules. , 1994, Annual review of immunology.

[166]  Wei Chen,et al.  Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. , 1994, Cancer research.

[167]  M. Astill,et al.  Detection of the extracellular domain of c‐erbB‐2 oncoprotein in sera from patients with various carcinomas: Correlation with tumor markers , 1993, Journal of clinical laboratory analysis.

[168]  D. Weiner,et al.  Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. , 1989, Oncogene.

[169]  A. Harris.  Letter: Vitamin-C-induced hyperoxaluria. , 1976, Lancet.